theMednetRegister

Triple negative   

Questions discussed in this category

Do you have a certain tumor size threshold in which you change chemotherapy recommendations for a small, triple negative breast cancer?
(For instance, TCx4 instead of ddAC->T for smaller tumors?)Does this affect your decision about treating with neoadjuvant versus adjuvant chemother...
5 Answers available
Would you consider adding pembrolizumab to adjuvant chemotherapy in a patient with stage 3 TNBC who did not receive neoadjuvant treatment?
What would be your approach to a patient who went straight to surgery due to HR+ biopsy, but found to be triple negative on surgical pathology? 
4 Answers available
Would you recommend adjuvant endocrine therapy in combination with immunotherapy for triple negative metaplastic breast cancer with residual disease that is ER strongly positive?
1 Answer available
Would ITCs in a single axillary node push you towards recommending adjuvant chemotherapy for a young woman with a T1a (<2mm) triple negative breast cancer?
Patient underwent an axillary dissection with ITCs in 1/23 nodes.
1 Answer available
How would you treat a young premenopausal female with triple negative inflammatory breast cancer who progressed on carboplatin/paclitaxel/pembrolizumab (KEYNOTE 522), but didn't receive anthracycline portion and has a positive BRCA2 mutation?
1 Answer available
How do you treat a female with a diagnosis of invasive apocrine carcinoma of the breast?
As expected triple negative.
1 Answer available
What would be your treatment approach in a premenopausal BRCA2+ patient with cT2N0 grade 2-3, ER negative, PR variably positive (30%; staining weak to high), HER2 negative breast cancer?
Would you still treat with neoadjuvant KEYNOTE-522? 
3 Answers available
Would you offer neoadjuvant chemoimmunotherapy per KEYNOTE 522 for a patient with clinical stage IIB triple-negative breast cancer with apocrine histology or recommend surgery first?
2 Answers available
How do you manage therapy in an elderly, >80 years of age, patient with triple-negative breast cancer that is not a surgical candidate?
2 Answers available
Do you give systemic therapy for triple negative breast cancer with brain metastasis and no other sites of disease?
Following SRS to the brain lesions, is it safe to closely follow the patient for recurrence?
4 Answers available
Would you consider chemoimmunotherapy (CP-Pembro-AC) in triple negative breast cancer if tumor is not palpable on physical exam?
If yes, how do you assess the tumor response and how frequently while on neoadjuvant chemoimmunotherapy?
1 Answer available
How would you treat a patient with TNBC with a residual strongly PR+, ER- breast mass on mastectomy after neoadjuvant KEYNOTE 522 based chemoimmunotherapy?
Would you consider using endocrine therapy, pembrolizumab, capecitabine, or CDK 4/6 inhibitor?
1 Answer available
What is your preferred adjuvant chemotherapy regimen for a patient with local recurrence of TNBC two years after completing neoadjuvant ddAC-T who declined prior adjuvant capecitabine?
Had mastectomy resulting in ypT1cN1a. Post menopausal female with good PS. 
1 Answer available
In metastatic TNBC with germline or somatic BRCA mutation, when is the preferred time to introduce a PARP inhibitor?
In which scenarios would you consider a parp inhibitor as the first line treatment of choice? 
6 Answers available
How do you decide between 1st line PARPi or immunotherapy in a patient with metastatic gBRCA mutated TNBC?
Received neoadjuvant ddAC/T followed by adjuvant capecitabine for residual disease and found to have metastatic pulmonary nodules within months of sur...
4 Answers available
Would you consider omitting platinum from neoadjuvant chemotherapy in women > 50 years of age with localized triple negative breast cancer?
The results presented by Sudeep Gupta (from the Tata Memorial Breast Group at 2022 San Antonio Breast Cancer Symposium #GS5-01) showed no benefit (pCR...
2 Answers available
What neoadjuvant therapy will you give to a premenopausal woman with cT2N0 metaplastic triple negative breast cancer?
3 Answers available
How do you approach continuation versus cessation of systemic therapy for patients with stage IV triple negative breast cancer with a prolonged complete response to therapy and who are tolerating therapy well?
1 Answer available
What would be your regimen of choice for a healthy 80+ year old with localized triple negative breast cancer?
Would you give anthracycline based regimen in a patient with stage III TNBC?
3 Answers available
Is APBI appropriate in post menopausal women with small, triple negative breast cancers excised with negative margins?
3 Answers available
Would you offer neoadjuvant chemotherapy to cT1c N0 triple negative breast cancer with metaplastic features in a young patient?
2 Answers available
Do you recommend maintenance immunotherapy after CR on chemotherapy for patients with metastatic TNBC?
In patients with prior perioperative immunotherapy with early relapse, would re-introduction of immunotherapy be reasonable with high TMB? 
2 Answers available
What neoadjuvant regimen would you give a patient with multicentric IDC consisting of TNBC and concurrent ER/PR- HER2+ breast cancer with ER/PR- HER2+ axillary LN mets?
2 Answers available
How would you approach a young patient with oligometastatic inflammatory triple negative breast cancer with bone only metastases?
Would you consider definitive local therapy (surgery, radiation?) if she achieved a good response to initial systemic therapy?
3 Answers available
What treatment would you provide for a patient with bilateral synchronous locally advanced cT4dN0 TNBC and cT1b ER+ HER2+ breast cancer?
Would you proceed with KEYNOTE 522 regimen and add anti-HER2 targeted therapy adjuvantly?
2 Answers available
Would you consider avoidance of AC and proceeding to surgery in a cT2N0 TNBC patient who achieves a significant clinical response to carboplatin, paclitaxel, and pembrolizumab as part of the KEYNOTE-522 regimen?
What scenarios would you do second neoadjuvant treatment vs surgery?
1 Answer available
What adjuvant chemotherapy regimen do you recommend for a patient with T1cN0 TNBC?
If said patient was known to be gBRCA mutated, would you use neoadjuvant chemotherapy to enable adjuvant olaparib for those that did not have a pCR? &...
4 Answers available
Would you offer reirradiation after resection of locally recurrent triple negative breast cancer only 6 months after completion of postmastectomy radiation?
2 Answers available
Do you plan to offer adjuvant olaparib to all gBRCA+ breast cancer whether TNBC or HR+?
In subset analyses of OlympiA there seems to be smaller magnitude of benefit among HR+ patients. In your opinion, should adjuvant olabarib be offered ...
3 Answers available
In patients who receive neoadjuvant pembrolizumab and chemotherapy for TNBC, how will you manage adjuvant treatment if they have a germline BRCA mutation?
Would you continue pembrolizumab? Would you introduce olaparib? If using both, how would you sequence? 
5 Answers available
How do you sequence capecitabine and olaparib, if at all, in patients with BRCA+ TNBC and residual disease after neoadjuvant chemotherapy?
5 Answers available
Which systemic therapy (if any) do you offer premenopausal women with a second TNBC local resectable recurrence and an extensive chemotherapy history?
Patient has already received neo/adjuvant treatment with AC, paclitaxel, capecitabine, docetaxel, and carboplatin.
1 Answer available
How would you approach systemic therapy for a young post-menopausal woman with locoregional TNBC chest wall recurrence treated with definitive radiation?
Patient previously received neoadjuvant ddAC-T with residual disease at surgery, followed by adjuvant capecitabine which was completed 2 months prior ...
1 Answer available
Would you consider adjuvant olaparib in a premenopausal female with TNBC with high risk features and germline BRCA1 mutation who achieved pCR after neoadjuvant chemotherapy?
Does not meet Olympia trial indication
1 Answer available
Would you consider treatment with sacituzumab in triple negative metastatic breast cancer if there has been progression on irinotecan?
Given sacituzumab is an antibody drug conjugate of the active metabolite of irinotecan
4 Answers available
In which scenarios would you utilize sacituzumab govitecan earlier than third line in the treatment of metastatic TNBC?
Given seemingly improved efficacy in ASCENT patients who had less prior treatment, would you consider use after only one prior agent rather than two? ...
4 Answers available
How has the ASCENT trial impacted your management of previously treated metastatic TNBC?
Are there specific patient cohorts in whom you will more preferentially use sacituzumab govitecan? Can data from ASCENT be applied to patients with C...
3 Answers available
Would you consider hormone replacement therapy in young women with germline BRCA1 mutation and history of triple negative breast cancer who underwent bilateral mastectomy and prophylactic bilateral salpingo-oophorectomy?
This situation can feel uncomfortable.  Would this feel safer if patient is s/p mastectomy and had TNBC?
1 Answer available
How do you modify TNBC neoadjuvant chemotherapy in patients with multiple sclerosis?
1 Answer available
Do you recommend testing for UGT1A1 prior to initiating sacituzimab govitecan for patients with metastatic TNBC to mitigate neutropenia risk?
2 Answers available
Are there known biomarkers predictive of response or resistance to sacituzumab govitecan which should be incorporated into treatment decisions for metastatic TNBC?
Are there differences in outcome among the BRCA mutated subgroup, or others?
2 Answers available
How do you counsel patients with metastatic TNBC on their various treatment options after progression on first line regimens?
To what degree do you factor in patient preference when choosing among available treatments? Are there features of each regimen that you emphasize in ...
3 Answers available
For a young patient who had a prior pCR to neoadjuvant therapy, would you consider systemic therapy after local resection and radiation of an isolated brain metastatic recurrence of triple negative breast cancer?
CNS recurrence occurred within two years of prior neoadjuvant therapy
1 Answer available
Which chemotherapy regimen would you recommend for locally recurrent TNBC several years after therapy with docetaxel + cyclophosphamide for four cycles?
1 Answer available
For patients with metastatic triple negative breast cancer on nab-paclitaxel + atezolizumab who have an ongoing response, are you continuing immunotherapy after the FDA withdrawal of atezolizumab?
1 Answer available
For patients with triple negative breast cancer, currently undergoing neoadjuvant dd AC, would you consider adding pembrolizumab to weekly paclitaxel based on recent KEYNOTE-522 and continue as adjuvant?
2 Answers available
In a patient with localized TNBC, how would you decide in whom to perform breast MRI prior to starting neoadjuvant systemic therapy?
1 Answer available
What chemotherapy backbone will you use with pembrolizumab in the neoadjuvant setting for triple negative breast cancer?
Will you incorporate carboplatin into the backbone as it was done in the KEYNOTE trial?
2 Answers available
In a patient with metastatic TNBC on chemoimmunotherapy for several years and a near complete response, would you consider an immunotherapy holiday?
The patient was started on chemoimmunotherapy 3 years ago. Recent scans show small treated brain metastases (s/p RT several years ago) and no disease ...
2 Answers available
Would you consider surgical management of a TNBC primary after a patient has had radiographic resolution of oligometastatic disease?
Patient with T2N1 disease and isolated liver metastases. Axilla and liver completely responded to chemo + IO, but limited residual breast enhancement ...
2 Answers available
Will you incorporate immunotherapy in neoadjuvant treatment of triple negative breast cancer based off KEYNOTE-522?
Based on pCR and EFS data from KEYNOTE 522 and recent FDA approval?
2 Answers available
How would you approach an elderly patient with early stage TNBC with node negative disease?
1 Answer available
How late after completion of adjuvant capecitabine and radiation would you consider adjuvant olaparib for a patient with gBRCA mutated TNBC?
Given that olaparib was given within 12 weeks of completion of standard adjuvant therapy on the trial, will you still offer it to patients outside tha...
1 Answer available
Would you consider the use of ctDNA as part of surveillance in high risk TNBC patients?
In patients who have completed all adjuvant therapy. Similar test to what is available for stage 2 and 3 colon cancer patients by Natera.
2 Answers available
How do you approach adjuvant treatment of pT1cN0 metaplastic triple negative breast cancer?
Healthy 67 y/o woman, 1.5cm tumor, grade 3
1 Answer available
How do you approach adjuvant therapy for a premenopausal patient with a pathologic BRCA1 mutation whose TNBC had a complete response to neoadjuvant chemotherapy except for an ITC in one LN?
Patient was given ddAC + T
2 Answers available
What treatment would you offer for a patient with unresectable triple negative breast CA who remains unresectable after completion of dd AC-T?
Presuming that imaging does not show distant metastatic disease, what would you offer? What about if the patient were PD-L1 negative?
4 Answers available
How would you treat triple negative breast cancer involving a pericardial effusion?
Do you have any experience with intra-pericardial chemotherapy administration, and if so, in what cases?
1 Answer available
Are you more inclined to offer adjuvant chemotherapy for a post-menopausal woman after lumpectomy for a small TNBC who has a concurrent metastatic ER+ breast CA?
Any difference in recommendations if the patient was asymptomatic from her metastatic ER+ disease? (eg bone mets)
1 Answer available
Would you use first line combination immunotherapy with chemotherapy in patients with metastatic low ER/PR+ (<10%), HER2 negative breast cancer?
Given that trials excluded patients with low ER, PR for this approach. 
1 Answer available
How would you approach adjuvant systemic therapy for a patient with a history of localized triple negative breast cancer 7 years prior for which she received adjuvant AC-T, now presenting with another ipsilateral T1cN0 triple negative breast cancer?
Given the data from KEYNOTE-522, would you try to incorporate chemotherapy in the treatment regimen?
2 Answers available
When would you offer anthracycline based adjuvant chemotherapy for a T1cN0 TNBC?
Does tumor size impact your recommendation? High grade? Young patient age?
2 Answers available
Would you use alpelisib in patients with biopsy proven hormone negative metastatic breast cancer with a PIK3CA alteration?
Would it affect your decision whether original primary tumor and treatment was hormone positive or negative?
2 Answers available
What chemotherapy would you offer (if any) in a young patient after resection and radiation of a single site of metastatic PDL1 positive, triple negative breast cancer?
1 Answer available
How would you approach a patient with a T3 spindle cell metaplastic breast cancer?
1 Answer available
Which neoadjuvant chemotherapy regimen would you use in a young, premenopausal woman with a rapidly growing clinical node positive poorly differentiated TNBC with a germline PALB2 mutation?
Options: 1) ddAC-T- surgery- adjuvant capecitabine if residual disease 2) weekly taxol/carbo x 12 followed by dd AC x 4 3) Keynote 522- pembro/taxo...
2 Answers available
For PDL1 testing in triple negative breast cancer, is CPS by 22C3 equivalent to SP142 Ventana?
1 Answer available
Is there any data available regarding the benefit of adjuvant chemotherapy in patients with early stage, lymph node negative, triple negative adenosquamous breast cancers?
1 Answer available
Would you include carboplatin with an anthracycline and taxane for neoadjuvant treatment for triple negative inflammatory breast cancer?
1 Answer available
How do you approach using non-anthracycline based neoadjuvant treatment for triple negative breast cancer, especially in older patients with node negative disease?
For example: do you use docetaxel + cyclophosphamide (TC) x4 and what is the evidence for using such a regimen
1 Answer available
How would you approach timing of adjuvant chemotherapy in a Stage 1 TNBC lost to follow up for >1 month since surgery?
surgically confirmed node negative disease 
1 Answer available
Would you proceed to anthracycline based neoadjuvant regimen for locally advanced triple negative breast cancer without clinical response to neoadjuvant paclitaxel or proceed to surgery?
BRCA status unknown currently 
2 Answers available
How would you treat a locally recurrent triple negative breast cancer after achieving CR a year earlier to neoadjuvant ddAC-T, BCS and WBRT?
Would you consider use of immunotherapy with checking PDL1? What chemotherapy agents would you consider along with mastectomy/radiation?
1 Answer available
Would you change chemotherapy in metastatic TNBC with impending cord compression but other visceral disease stable?
Chemotherapy - Carbo/Gem (2nd line). PDL1 and BRCA negative. 
1 Answer available
How would you approach a patient who responded to CDK4/6 inhibitor/endocrine therapy combination for metastatic HR+,HER2- breast cancer who now has disease progression which is biopsy proven TNBC?
Progression was observed only in the breast and required palliative mastectomy (T4b TNBC)
1 Answer available
How would you manage a young patient with newly recurrent metastatic triple negative breast cancer less than a year after completing adjuvant chemotherapy and worsening liver function due to intrahepatic disease?
Patient completed adjuvant AC-T 8 months prior to recurrence. BRCA negative, foundation medicine NGS pending. 
2 Answers available
How would you manage a patient who develops pleural and skin metastases shortly after completing neoadjuvant ddAC-T and surgery for a locally advanced triple negative breast cancer?
PD-L1 is low and she has residual neuropathy from neoadjuvant paclitaxel.
5 Answers available
After WBRT, what systemic therapy would you favor for maximal CNS penetrance in a patient with triple negative metastatic breast cancer and multifocal CNS disease?
Is there any evidence for sacituzumab govitecan (IMMU-132) in this situation with progressive systemic disease after prior anthracycline and taxane?
1 Answer available
What is your initial treatment strategy for patients with TNBC who present with isolated bulky axillary and cervical adenopathy?
1 Answer available
How would you manage a patient with high risk triple negative breast cancer with metastatic disease after recent adjuvant AC-T?
Would you consider still immunotherapy even if aggressive disease vs single agent chemotherapy?
1 Answer available
Will you offer capecitabine for 1 year to all localized TNBC patients?
Does the SYSUCC-001 trial presented at ASCO 2020 change your practice?
1 Answer available
How would you approach a patient with a locoregional recurrence TNBC who requires neoadjuvant treatment?
Patient previously received neoadjuvant carboplatin, anthracycline and taxane regimen and is BRCA negative.
1 Answer available
In what scenarios would you incorporate platinum for patients with localized TNBC?
How does gBRCA status impact your decision?
3 Answers available
Do you consider the presence of multifocality to decide whether to offer adjuvant therapy for patients with node-negative, multiple pT1a triple negative breast cancers?
1 Answer available
How would you approach further systemic treatment after definitive local treatment for patients with locally advanced TNBC that had early local progression through neoadjuvant AC-T, adjuvant cape and adjuvant RT?
Would you incorporate platinum into your treatment or enroll in an adjuvant IO trial? 
1 Answer available
How do you determine whether to choose a non-anthracycline neoadjuvant chemotherapy regimen in a fit patient with TNBC?
Does the KN-522 data change your decision about chemo regimen?
3 Answers available
How would you approach a postmenopausal female with TNBC (with LN involvement) and CKD Stage 5?
History of Multiple Myeloma with renal failure currently on velcade.
1 Answer available
How would you approach a patient with a recent MI s/p DES who is being considered for neoadjuvant chemotherapy for TNBC?
2D Echo - Normal Ejection Fraction 
1 Answer available
How do you approach a patient with metastatic inflammatory TNBC at diagnosis with a good PS?
PDL1 status pending; BRCA wild type
1 Answer available
What is your preferred approach to metastatic PDL1 negative TNBC?
Does the results of the tnAcity trial influence your decision in choosing a 1st line option?
1 Answer available
How do you treat patients rendered NED after resection of an isolated lung recurrence of an early stage triple negative breast CA years after adjuvant chemotherapy?
2 Answers available
Can 5-FU be substituted for adjuvant capecitabine for a dialysis dependent patient with triple negative breast cancer s/p neoadjuvant chemotherapy followed by mastectomy showing small residual disease?
1 Answer available
Do you consider omitting adjuvant radiation therapy in an older patient with node positive TNBC who achieve pCR to neoadjuvant chemotherapy?
2 Answers available
In which patients with stage 1 triple negative breast cancer would you utilize neoadjuvant chemotherapy?
Why do the NCCN guidelines suggest using neoadjuvant therapy only for patients with T2 or greater tumors?
4 Answers available
How would you treat a patient with a known history of ER/PR 90% and HER2 negative who develops skeletal metastatic disease on adjuvant endocrine therapy but now ER is only 2% and is PR and HER2 negative?
Initially stage 1 disease with high risk Mammaprint recurrence risk completed adjuvant chemo 15 months ago. 
1 Answer available
How do you choose a neoadjuvant therapy regimen for a patient with a triple negative breast cancer and a synchronous ER-/Her2+ breast cancer?
3 Answers available
Would you consider using an anthracycline-based regimen again for a breast cancer patient who previously received doxorubicin 10 years prior?
What are your thoughts with the new KEYNOTE-522 regimen? Would you just use carbo/paclitaxel/pembro part of the regimen or give as much doxorubicin as...
1 Answer available
Do you recommend adjuvant capecitabine for a very small amount (2 mm, ypT1a) of residual invasive disease in TNBC patients following neoadjuvant chemotherapy and lumpectomy?
1 Answer available
What is your approach to patients with locally advanced triple negative breast cancer with residual disease at the time of surgery?
Are you using post-neoadjuvant Xeloda based on preliminary data from the CREATE-X trial? Does BRCA mutation influence your decision?
1 Answer available
Do you add a platinum agent to neoadjuvant chemotherapy for triple negative breast cancer in BRCA 1/2 mutation carriers?
If so, what regimen? 
2 Answers available
Would you use a platinum containing regimen in the adjuvant setting for a triple negative breast cancer patient with contraindications to anthracycline based therapy?
1 Answer available
Is there a preferential approach for systemic therapy for triple negative breast cancer patients with leptomeningeal disease?
In a patient with isolated leptomeningeal disease (no systemic disease), would you still recommend systemic therapy?
1 Answer available
What chemotherapeutic regimen would you prefer in patients with T1N0 triple-negative breast cancer, assuming no contraindications to taxanes and anthracyclines?
2 Answers available


Papers discussed in this category

ESMO Open, 2016-01-01
Highlights from the San Antonio Breast Cancer Symposium 2015.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003-03-15
Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009-03-10
Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-08-10
Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-02-01
Risk of marrow neoplasms after adjuvant breast cancer therapy: the national comprehensive cancer network experience.
Journal of the National Cancer Institute, 2024 Sep 30
Trends in breast cancer specific death by clinical stage at diagnoses between 2000-2017.
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2015-04
Treatment of leptomeningeal carcinomatosis: current challenges and future opportunities.
Am J Case Rep, 2017-02-28
Metronomic Capecitabine Effectively Blocks Leptomeningeal Carcinomatosis From Breast Cancer: A Case Report and Literature Review.
N. Engl. J. Med.,
Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-01-01
Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance).
Breast Cancer Res. Treat., 2014-09-01
Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-06-10
Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105.
Lancet Oncol., 2014-06-01
Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-04-01
Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype.
Cancer, 2004-10-15
Central nervous system metastases in patients with high-risk breast carcinoma after multimodality treatment.
JAMA Oncol, 2020 Aug 13
Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer: A Phase 3 Randomized Clinical Trial.
Lancet Oncol., 2013 Dec 19
Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3 trial.
J Natl Cancer Inst, 2018 Jun 1
Comparison of Neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results.
Oncology reviews, 2017-03-03
The Role of Carboplatin in the Neoadjuvant Chemotherapy Treatment of Triple Negative Breast Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009-10-01
Frequent pathologic complete responses in aggressive stages II to III breast cancers with every-4-week carboplatin and weekly paclitaxel with or without trastuzumab: a Brown University Oncology Group Study.
N. Engl. J. Med., 2017 Jun 04
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.
Clinical cancer research : an official journal of the American Association for Cancer Research, 2017-02-01
Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts.
British journal of cancer, 2012-08-21
PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2.
Int J Radiat Oncol Biol Phys,
Radiotherapy alone in breast cancer. I. Analysis of tumor parameters, tumor dose and local control: the experience of the Gustave-Roussy Institute and the Princess Margaret Hospital.
JAMA Oncol,
Adjuvant Capecitabine in Combination With Docetaxel, Epirubicin, and Cyclophosphamide for Early Breast Cancer: The Randomized Clinical FinXX Trial.
PLoS ONE, 2016 Oct 14
Capecitabine in Combination with Standard (Neo)Adjuvant Regimens in Early Breast Cancer: Survival Outcome from a Meta-Analysis of Randomized Controlled Trials.
Sci Eng Ethics, 2017 Sep 15
Conflict of Interest and the CREATE-X Trial in the New England Journal of Medicine.
Lancet, 2015 Mar 02
Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial.
International journal of radiation oncology, biology, physics, 2007-07-15
Postmastectomy radiation improves the outcome of patients with locally advanced breast cancer who achieve a pathologic complete response to neoadjuvant chemotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004-12-01
Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013-07-01
Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343.
Lancet Oncol., 2015-03-01
Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial.
Ann. Surg. Oncol., 2013 Nov 23
Breast-conserving surgery with or without radiotherapy in older breast patients with early stage breast cancer: a systematic review and meta-analysis.
NPJ Breast Cancer, 2016 Nov 16
Triple-negative breast cancer: the importance of molecular and histologic subtyping, and recognition of low-grade variants.
N Engl J Med, 2018 Oct 20
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.
N. Engl. J. Med.,
Pembrolizumab for Early Triple-Negative Breast Cancer.
Annals of oncology : official journal of the European Society for Medical Oncology, 2018-08-01
nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial.
Ann. Oncol., 2010 Jan 29
Proposal for dosage adjustment and timing of chemotherapy in hemodialyzed patients.
The New England journal of medicine, 2016-07-07
Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.
The Lancet. Oncology, 2018-04
Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
J Clin Oncol. , 2019 Sep 1
NAB-Paclitaxel Improves Disease-Free Survival in Early Breast Cancer: GBG 69-GeparSepto.
Breast cancer research and treatment, 2012-11
A randomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting. Results from the GEICAM/2006-03, multicenter study.
Breast Cancer Res Treat, 2014 Apr 12
Randomized phase II study of weekly paclitaxel with and without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA breast cancer without HER2 overexpression.
J. Clin. Oncol., 2019 Dec 05
Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01).
The New England journal of medicine, 2018-08-23
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009-05-20
Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-04-10
Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR Trial.
Chest,
Long-term results of intrapericardial chemotherapeutic treatment of malignant pericardial effusions with thiotepa.
Interact Cardiovasc Thorac Surg, 2014 Aug 20
Palliative treatment for symptomatic malignant pericardial effusion†.
Clinical cancer research : an official journal of the American Association for Cancer Research, 2018-12-01
Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel.
N Engl J Med,
Micrometastases or isolated tumor cells and the outcome of breast cancer.
JAMA Oncol, 2016 Mar
Delayed Initiation of Adjuvant Chemotherapy Among Patients With Breast Cancer.
J. Clin. Oncol., 2016 Jan 19
Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V.
Lancet, 2020 Sep 20
Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial.
NPJ breast cancer, 2017
Dramatic response of metaplastic breast cancer to chemo-immunotherapy.
JAMA Oncol,
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial.
J Clin Oncol, 2020 Jan 13
Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update.
Cancer, 2017-10-01
Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics.
Clinical breast cancer, 2008-06
Phase I/II study of ixabepilone plus capecitabine in anthracycline-pretreated/resistant and taxane-resistant metastatic breast cancer.
Breast Cancer Res, 2020 Nov 04
A comprehensive overview of metaplastic breast cancer: clinical features and molecular aberrations.
Breast Cancer Res Treat, 2011 Jul 27
Lack of efficacy to systemic chemotherapy for treatment of metaplastic carcinoma of the breast in the modern era.
Clin Breast Cancer, 2019 May 24
Adjuvant Treatment of Triple-Negative Metaplastic Breast Cancer With Weekly Paclitaxel and Platinum Chemotherapy: Retrospective Case Review From a Single Institution.
Annals of oncology : official journal of the European Society for Medical Oncology, 2019-04-01
OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer.
N Engl J Med, 2021 Jun 03
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer
BMC Cancer, 2018 Mar 07
Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history.
N Engl J Med,
Olaparib for Metastatic Germline BRCA-Mutated Breast Cancer.
JCO Oncol Pract, 2022 Jan 07
Q and A: A New Standard of Care for Germline and/or Mutation Carriers With Early-Stage Breast Cancer.
JAMA Oncol,
Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer.
Ann Oncol,
Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto.
J Clin Oncol, 2021 Jun 06
Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131.
Lancet Oncol, 2020 Aug 06
Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study.
JAMA Oncol,
Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial.
Am J Surg Pathol, 2021 Jun 10
PD-L1 Expression in Metaplastic Breast Carcinoma Using the PD-L1 SP142 Assay and Concordance Among PD-L1 Immunohistochemical Assays.
Mol Cell Endocrinol, 2021 Jan 26
Hormone replacement therapy after breast cancer: Yes, No or maybe?
Cancer Discov, 2021 Aug 17
Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-Negative Breast Cancer.
Ann Oncol, 2021 Mar 16
Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial.
Annals of oncology : official journal of the European Society for Medical Oncology, 2001-09
Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer.
N Engl J Med, 2021 Apr 22
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.
Cochrane Database Syst Rev, 2021 May 26
Capecitabine for hormone receptor-positive versus hormone receptor-negative breast cancer.
Radiother Oncol, 2011-08-01
Adjuvant chemotherapy and radiotherapy in triple-negative breast carcinoma: a prospective randomized controlled multi-center trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011-07-20
Increased risk of locoregional recurrence for women with T1-2N0 triple-negative breast cancer treated with modified radical mastectomy without adjuvant radiation therapy compared with breast-conserving therapy.
International journal of radiation oncology, biology, physics, 2012-11-01
External beam accelerated partial-breast irradiation using 32 gy in 8 twice-daily fractions: 5-year results of a prospective study.
Annals of surgical oncology, 2013-10
Locoregional recurrence following accelerated partial breast irradiation for early-stage invasive breast cancer: significance of estrogen receptor status and other pathological variables.
Lancet, 2019 Dec 14
Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial.
Lancet Reg Health West Pac, 2021 May 13
Anthracycline-free or short-term regimen as adjuvant chemotherapy for operable breast cancer: A phase III randomized non-inferiority trial.
J Clin Oncol, 2021 Jan 28
Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline.
J Clin Oncol, 2017 Jun 29
Adjuvant Cyclophosphamide and Docetaxel With or Without Epirubicin for Early TOP2A-Normal Breast Cancer: DBCG 07-READ, an Open-Label, Phase III, Randomized Trial.
J Clin Oncol, 2022 Jan 19
CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer.
N Engl J Med, 2015 Jan 8
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.
J Clin Oncol, 2022 Jan 07
Early Local Therapy for the Primary Site in De Novo Stage IV Breast Cancer: Results of a Randomized Clinical Trial (EA2108).
Oncotarget,
Outcomes of patients with inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes: A population-based study from the SEER program.
J Clin Oncol, 2019 Nov 04
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.
Cancer Discov, 2020 Nov 02
Tumor Mutational Burden as a Predictive Biomarker in Solid Tumors.
N Engl J Med, 2022 Jun 05
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.
Ann Oncol, 2021 Jul 01
First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis.
The New England journal of medicine, 1987-12-10
Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies.
Korean J Intern Med, 2020 Feb 28
Maintenance chemotherapy after 6 cycles of platinum-doublet regimen in anthracycline-and taxane-pretreated metastatic breast cancer.
Clin Cancer Res, 2020 Nov 18
Randomized Phase II Trial of Anthracycline-free and Anthracycline-containing Neoadjuvant Carboplatin Chemotherapy Regimens in Stage I-III Triple-negative Breast Cancer (NeoSTOP).
Int J Cancer, 2021 Oct 07
Neoadjuvant docetaxel plus carboplatin vs epirubicin plus cyclophosphamide followed by docetaxel in triple-negative, early-stage breast cancer (NeoCART): Results from a multicenter, randomized controlled, open-label phase II trial.
Annals of oncology : official journal of the European Society for Medical Oncology, 2022 Oct 10
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer.
Clinical breast cancer, 2022 May 05
Characterization of Weakly Hormone Receptor (HR)-Positive, HER2-Negative Breast Cancer and Current Treatment Strategies.
Journal of clinical medicine, 2022 Mar 14
Triple-Negative Apocrine Breast Carcinoma Has Better Prognosis despite Poor Response to Neoadjuvant Chemotherapy.
Breast (Edinburgh, Scotland), 2020 Jul 24
Prognosis of selected triple negative apocrine breast cancer patients who did not receive adjuvant chemotherapy.

Related Topics

Copyright © 2024 theMednet
All Rights Reserved.